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Accepted 3 October 2005Phenotypic discordance for schizophrenia in monozygotic twins clearly indicates
involvement of environmental factors as key determinants in disease development.
Positive findings from genome scans, linkage and association studies apply in only a
minority of those affected, while post-mortem brain investigations reveal altered
expression of genes and proteins involved in numerous neurodevelopmental, metabolic
and neurotransmitter pathways. Such altered expressions could result, on the one hand,
frommutations in coding regions or polymorphisms in the promoter and regulatory regions
in genes within those areas identified by gene searches or, on the other hand, from
inadequate amounts of modulators, transporters and synthesizers of transcription factors
necessary for regulation of the putative genes. Hormones and vitamins are such
modulators. They could serve as bridges between genes and environment in
schizophrenia. Multiple evidence supports the suggestion of retinoids and thyroid
hormones as plausible actors in these roles. Both are not only essential for normal
development of the central nervous system but also regulate the expression of many
neurotransmitters, their synthesizing enzymes and receptors, and other genes in broader
signaling transduction cascades affecting pathways that are altered in response to
treatment. Functional and positional candidate genes include retinoic acid and thyroid
hormone receptors, retinaldehyde dehydrogenases and deiodinases, which synthesize the
powerful morphogens, retinoic acid and triiodothyronine, and the enzymes involved in
their inactivation. This review highlights selective evidence supporting the retinoid and
thyroid hormone hypotheses of schizophrenia.
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While there is strong evidence supporting genetic causa-
tion in schizophrenia, epigenetic and environmental fac-
tors are also believed to play a major role in the
disease onset (Goodman, 1998; Mackay-Sim et al., 2004;
Owen et al., 2004; Ozer et al., 2004; Sharma, 2005;
Suzuki et al., 2004; Tsuang et al., 2001). Recently, some
success has been achieved in identifying significant in-
volvement of single genes across several different ethnic
or population groups but in no instance has there been
total replication of such involvement across all groups
studied. The disease is thought to be initially character-
ized by diverse neurodevelopmental insults occurring in
the later half of gestation, with the subsequent combi-
nation of both genetic vulnerabilities and environmental
stressors resulting in the usual age of onset in mid-to-late adolescence. Based on response to treatment, vari-
ous neurotransmitter cascades have been implicated in
the etiology of schizophrenia, with special emphasis on
the dopaminergic hypothesis in which schizophrenia
results from increased dopaminergic stimulation in the
limbic system.
In view of the lack of wide replicability of genome-wide
scans and inconclusive results from association studies of
missense and nonsense mutations such as those respon-
sible for simple genetic disorders, the approach to study
this complex disease has broadened to include investiga-
tions and functional analyses of human promoter poly-
morphisms. There are hopes that such approaches will
prove productive for recent studies have shown a large
proportion of genes with polymorphic promoters (Buckland
et al., 2004; Hoogendoorn et al., 2003; Perkins et al., 2005)
responsible for altered gene expression. It is possible that,
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phrenia results from the altered expression of normal
genes (Goodman, 1996a). In addition to discrete mutations
in coding regions, altered expression of candidate genes
could result either from polymorphisms in the promoter
and regulatory regions of the genes or from inadequate
supply of modulators of transcription factors activity
(Nobel et al., 2001).
Transcriptional factors and their ligands (such as hor-
mones and vitamins) are promising candidates in the link
between the genetic and environmental components of
complex diseases such as schizophrenia. The genetic cas-
cades which make ligands available to activate nuclear
transcription factors at specific times in development and
at specific cellular locations are complex. Normal allelic
variants in any of the metabolic enzymes of the cascadeFig. 1 – Overview of thyroid hormone and retinoid transport, m
retinoid in circulation enter the cells and are converted into thei
The activated hormone/vitamin that enters the nucleus, upon bi
Thyroid hormone and retinoids also target cell membrane recep
with TAAR1, and intracellular signaling transduction pathways.
binding protein; CRBP, cellular retinol-binding protein; CYP, cyto
peroxisome-proliferator-activated receptor; ALDH1, retinaldehyd
binding protein; REH, retinyl ester hydrolase; RDH, retinol dehyd
thyroxine; TAAR, trace-amine-associated receptor; TBG, thyroxin
transthyretin.or of the ligand transporters could combine to alter ligand
availability.2. Thyroid hormone and vitamin Ametabolism
and mode of action
Fig. 1 summarizes major pathways of thyroid hormone and
vitamin A metabolism and their interaction at the level of
gene transcription regulation. Roles in schizophrenia of
thyroid hormone and vitamin A have been proposed, and
evidence supporting this hypothesis has been summarized
(Goodman, 1998). The purpose of this article is to update
the hypothesis with new data that have appeared in the
literature, most of them post-2003. These new data aid in
the interpretation of the already existing hypothesis.etabolism and mechanisms of action. Thyroid hormone and
r active forms or inactivated by specific metabolic pathways.
nding to nuclear receptors, influences gene expression.
tors, as exemplified by the interaction of 3-iodothyronamine
ADH, alcohol dehydrogenase; CRABP, cellular retinoic acid
chrome P450; LRAT, lecithin–retinol acyltransferase; PPAR,
e dehydrogenase; RAR, retinoic acid receptor; RBP, retinol-
rogenase; RXR, retinoid X receptor; T3, triiodothyronine; T4,
e-binding globulin; THR, thyroid hormone receptor; TTR,
4 B R A I N R E S E A R C H R E V I E W S X X ( 2 0 0 5 ) X X X – X X X
ARTICLE IN PRESS2.1. Thyroid hormone
Thyroid hormones are essential for cellular metabolism,
growth and differentiation of several organs including the
brain (Bernal, 2002; Yen, 2001). Synthesis of thyroxine (T4),
the major product secreted by the thyroid gland, requires the
active uptake of dietary iodine by the gland. Regulation of
thyroid hormone secretion is tightly regulated by the pituitary
thyroid-stimulating hormone (TSH) (gene acronyms/abbrevia-
tions and gene names are specified in accordance with the
HUGO Gene Nomenclature Committee at http://www.gene.
ucl.ac.uk/nomenclature/) and by the hypothalamic thyrotro-
pin-releasing hormone. A feed-back mechanism exists in
which thyroid hormone and retinoic acid can suppress the
expression of the TSH gene (Wolf, 2002). In the circulation, T4
is mainly bound to plasma proteins, namely thyroxine-bind-
ing globulin, transthyretin (TTR), albumin and lipoproteins
(Palha, 2002). Triiodothyronine (T3), the biologically most ac-
tive thyroid hormone, derives from T4 deiodination (Bianco et
al., 2002). In the periphery, type I deiodinase in the kidney and
liver is responsible for producing most of the circulating T3. In
the brain, T3 is produced for local use by the action of deiodi-
nase type II. Interestingly, deiodinases type I and II are differ-
entially regulated in order to protect the brain from T3 excess
or deficiency. In accordance, during hypothyroidism, type I
deiodinase is downregulated while type II is upregulated; the
opposite occurs in hyperthyroid conditions. Therefore, the
activity of deiodinases is a key step to regulate the availability
of active T3. Inactivation of thyroid hormone is mainly carried
out by the action of type III deiodinase, glucoronosyltransfer-
ase and sulfotransferases (Leonard and Koehrle, 2000).
Most thyroid-hormone-mediated actions are controlled by
transcriptional regulation (Bassett et al., 2003; Yen, 2001). T3
interacts with thyroid hormone receptors (THR) that function
as ligand-activated transcription factors. Two genes encode
THRs, THRA and THRB, and for each there are splicing var-
iants with distinct developmental and tissue distribution pat-
terns. Within the nucleus, THRs recognize hormone response
elements in target genes. For activity, however, they need to
heterodimerize. The retinoid X receptor (RXR) is their princi-
pal heterodimeric partner. The metabolism of thyroid hor-
mones and retinoids is, therefore, linked through their main
mechanism of action at the transcription level. However, as
we will see below, other bridges link these two important
classes of gene expression modulators.
2.2. Retinoids
Vitamin A (retinol) is obtained from the diet and derives either
from preformed vitamin A or from provitamin A carotenoids.
In the circulation, vitaminAmay travel unbound in the formof
retinol, which can lead to toxicity (Gimeno et al., 2004), or
preferably is either carried in lipoprotein particles in the form
of retinyl esters, or as a retinol/retinol-binding protein (RBP)
complex bound to TTR. Thus, TTR serves as a carrier for both
retinol bound to RBP and T4 in blood and in cerebrospinal fluid
(CSF). In the CSF, TTR may transport retinol to sites where the
primary morphogens of the retinoid cascade, the biologically
active molecules, 9-cis or all-trans retinoic acid (RA) are syn-
thesized through the action of several hydrolases, transferasesand dehydrogenases (particularly the retinaldehyde dehydro-
genases, ALDH1A1, 2 and 3) (Gottesman et al., 2001; McCaffery
and Drager, 1994) and inactivated by the cytochrome P450
enzymes, CYP26A1, B1 and C1 (Taimi et al., 2004). Retinoid
activity ismainly achieved by transcription regulation through
interaction with two types of nuclear receptors that display
different ligand specificity (Balmer and Blomhoff, 2002). All-
trans RA preferentially binds to RARs (A, B and G), while 9-cis
RA binds both RAR and RXRs (A, B and G). These receptors
belong to the same family as the THRs and, as well, hetero-
dimerize and interact with specific response elements on tar-
get genes. Interestingly, RXR is a promiscuous partner with
RAR, THRs, peroxisome-proliferator-activated receptors, vita-
min D receptor (Mackay-Sim et al., 2004) and also nuclear
receptors for which no ligand has been discovered, such as
the NR4A2 (Wallen-Mackenzie et al., 2003). Thyroid hormones
and retinoid pathways are therefore related and influenced by
each other, not only because they share blood and CSF specific
carriers, but also because their nuclear receptors frequently
heterodimerize to regulate gene transcription.
For most of the hormones and vitamins influencing gene
expression, studies clearly suggest that these molecules can
exert functions independent of their nuclear receptors. While
nuclear-transcription-mediated actions take hours to days to
manifest, rapid actions outside the nucleus have been
reported, demonstrating mechanisms independent of tran-
scription. These can be exerted by interaction of T4 or T3 with
plasma membrane receptors, cytoplasm and cell organelles
(Bassett et al., 2003; Davis et al., 2002; Weitzel et al., 2003) or
through hormone intermediates or metabolites. A novel iden-
tified thyroid hormone derivative, 3-iodothyronamine, has
been shown, in vitro, to be a potent agonist of the G-protein-
coupled trace-amine-associated receptor 1 (TAAR1) (Scanlan
et al., 2004). RA is a major modulator of apoptosis, involving
gene activationwithinmitochondriawhich are independent of
the nuclear RARs (Pfahl and Piedrafita, 2003). This suggests
that RA analogs might be uniquely successful in the develop-
ment of therapies (Farooqui et al., 2004) to counter these ex-
cessive apoptotic mechanisms that have been proposed as
malignant actors in a variety of neuropsychiatric disorders
including schizophrenia (Goodman, 1998; LaMantia, 1999;
Sharma, 2005), affective disorder (Sakai et al., 2004) andAlzhei-
mer's disease (Corcoran et al., 2004; Etchamendy et al., 2001;
Goodman and Pardee, 2003; Ono et al., 2004). In addition, some
data also implicate RA in gene expression regulation through a
direct role in the activation of transcription factors such as the
phosphorylation of cyclic AMP response element binding pro-
tein (Canon et al., 2004). Moreover, retinoid and thyroid hor-
mone receptors can act independently of ligands particularly
as mediators of cell fate, gene silencing, co-factor recruitment
and chromatin remodeling (Weston et al., 2003), all of which
processes having been proposed as increasing vulnerability to
schizophrenia (Abdolmaleky et al., 2004; Sharma, 2005).3. Thyroid hormones, retinoids and schizophrenia
Thyroid hormones and retinoids are not only essential for the
proper development of the central nervous system (Maden,
2002; Morreale de Escobar et al., 2004) but also for the adult
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cesses that have been identified as pathological in schizo-
phrenia are regulated by retinoids and thyroid hormones.
These include differentiation of the cerebellum, axonal migra-
tion and myelination (Rodriguez-Pena, 1999), control of later-
alization and symmetry of the developing embryo (Vermot
and Pourquie, 2005; Vermot et al., 2005), cell survival in adult
hippocampus (Crandall et al., 2004), transcriptional regulation
of enzymes, receptors and transporters of the neurotransmit-
ter cascades (Balmer and Blomhoff, 2002; Bernal et al., 2003;
Smith et al., 2001), such as the dopamine D2 receptor (Samad
et al., 1997), and maturation of the limbic regions of the fore-
brain (Luo et al., 2004). Retinoid deficit leads to defects in
lateralization and symmetry and ventricular enlargement
(Goodman, 1996b; Kawakami et al., 2005; Vermot and Pour-
quie, 2005; Vermot et al., 2005). Mice exposed to high levels of
retinoic acid during a critical period in early development,
corresponding to the second trimester in utero for humans
exhibit severely abnormal limbic system-mediated behaviors
as adults, e.g., extreme aggressiveness and poor grooming,
which may be considered as modeling schizophrenia, al-
though they appear normal as pups (Luo et al., 2004). And,
retinoids and thyroid hormone have been directly implicated
in the processes of learning and memory (Zoeller and Rovet,
2004), particularly working memory (Wietrzych et al., 2005),
which is intricately involved not only in language production
but also in schizophrenia (Mitchell and Crow, 2005).
Major thyroid hormone deficiency during pregnancy
results in cretinism, while mild hypothyroidism is associated
with poorer cognitive development. Even euthyroid hypothyr-
oxinemia during pregnancy has been shown to impair proper
neuronal migration in the somatosensory cortex and hippo-
campus in rodents (Lavado-Autric et al., 2003). This is believed
to impair behavior, as recently shown inmice deprived of TTR.
These mice are euthyroid hypothyroxinemic but display in-
creased exploratory activity and reduced signs of depressive-
like behavior (Sousa et al., 2004). Future studies will address
whether TTR-null mice have altered acute startle response as
ameasure of schizophrenia-like behavior. Followup of thyroid
function throughout pregnancy and evaluation of the psycho-
motor development of the offspring, possibly until adulthood,
would clearly be a more relevant indication of a relationship
between thyroid hormones and behavior disorders such as
schizophrenia. This is currently ongoing in several laborato-
ries, including ours. In the adult, it is known that thyroid
hormone fluctuations are associated with mood alterations,
and normal brain metabolism adapts in order to avoid thyroid
hormones excess or deprivation (Bianco et al., 2002).
Deficiency of thyroid hormones in neurodevelopment is
known to result in impaired proliferation, migration and dif-
ferentiation of hippocampal and cortical neurons (Auso et al.,
2004; Lavado-Autric et al., 2003). The expression of TRH in
humans is predominant in the left hemisphere (Borson-Cha-
zot et al., 1986), and asymmetries have been described for
several neuroendocrine system, including the hypothalamic–
thyroid axis (Gerendai and Halasz, 1997). Such pathologies
have been demonstrated in schizophrenia (Mitchell and
Crow, 2005).
Several studies, cited as follows, have reported thyroid
hormone level abnormalities in hospitalized schizophrenicpatients, but, in most cases, patients remain clinically euthy-
roid. Elevated and normal total T4 levels have been reported in
drug naive and acute schizophrenic patients and are de-
scribed to normalize or decrease, respectively, as a response
to treatment with different drugs (Baumgartner et al., 2000;
Kelly and Conley, 2005; Martinos et al., 1986; Rao et al., 1984;
Rinieris et al., 1980). Other studies reported a positive correla-
tion between circulating free T4 and free T3 with severity of
disease (Sim et al., 2002). These results are difficult to compare
and interpret given the different methodological approaches
and patient selection used in each study. Further studies are
certainly required to clarify the reasons for altered thyroid
hormone circulation levels in schizophrenia. Among these
are competition between thyroid hormones and medication
for commonmetabolic pathways, and the downstream effects
of therapeutic medication targets on the pituitary–thyroid
axis. It is particularly interesting to relate the pituitary–thy-
roid axis with the dopaminergic hypothesis of schizophrenia.
Increased dopaminergic activity inhibits TSH pituitary secre-
tion (Rao et al., 1984), and dopamine blockers result in sub-
clinical hypothyroidism (Magliozzi et al., 1989) while
hypothyroidism induces increased dopamine receptor sensi-
tivity (Crocker et al., 1986). A recent report demonstrated that
hypothyroid rats are unable to switch the conversion of excit-
atory to inhibitory hippocampus dopamine receptors, which
can be reversed by administration of T4. Therefore, hypothy-
roidism may compromise glutamatergic transmission and
synaptic function (Suzuki et al., 2004). Thyroid hormones
have been implicated in other neurotransmitter systems.
Studies in mentally healthy individuals showed that the pitu-
itary–thyroid state correlates with central dopaminergic and
serotonergic activity (Strawn et al., 2004). Given the distribu-
tion pattern of thyroid hormones in the brain and the strong
co-localization with the noradrenergic system (Rozanov and
Dratman, 1996), Dratman and Gordon have proposed that T3
itself might behave as a neurotransmitter (Dratman and Gor-
don, 1996). Of relevance here is the finding that 3-iodothyro-
namine, a recently identified endogenous derivative of
thyroid hormones, is able to activate, in vitro, the trace-
amine-associated receptor, TAAR1 (Scanlan et al., 2004).
TAARs are ligand targets of endogenous trace amines and of
several psychoactive drugs, including amphetamine deriva-
tives (Bunzow et al., 2001). The finding that a member of the
class of thyroid hormones acts as an endogenous ligand for at
least one of the TAARs brings a new perspective to the field of
thyroid hormone metabolism (Fig. 1) and suggests novel pos-
sibilities in terms of causality of and treatment for neurobe-
havioral disorders (Lindemann and Hoener, 2005).
Retinoids, too, modulate neurotransmission. Not only has
the expression of dopamine 2 receptors been shown to be
regulated by retinoic acid (Samad et al., 1997), but also single
and compound null mutations for the RARB, RXRB and RXRG
in mice demonstrate reduced expression of D1 and D2 recep-
tors and impaired dopamine signaling (Krezel et al., 1998).
Retinoid analogs have therefore been proposed as candidates
in the treatment of schizophrenia (Citver et al., 2002; Good-
man, 1998; Sharma, 2005). It is also interesting that a few
studies showed the beneficial effect of retinoid agonists in
suppressing side effects of antipsychotic drugs such as halo-
peridol. Specifically, 9-cis retinoic acid has been shown to
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mice (Ethier et al., 2004a) and the retinoid agonist docosahex-
aenoic acid reduced haloperidol-induced oral dyskinesias
(Ethier et al., 2004b).
Two very convincing studies have shown that nutritional
deprivation during early uterine life significantly increases
risk of schizophrenia among those so exposed (Susser and
Lin, 1992; St Clair et al., 2005). Although vitamin A is not the
only nutritional element compromised in cases of starvation,
it certainly represents a prime component in all starvation
supplemental nutrition programs and should be considered
as one of the factors that are compromised during severe
famine.
3.1. Chromosomal loci for schizophrenia
We will next briefly report evidence that chromosomal
regions implicated in schizophrenia harbor genes from the
vitamin A and thyroid hormone metabolic cascades. In 1998,
a review summarizing the findings that then supported the
retinoid hypothesis in schizophrenia was published (Good-
man, 1998). That paper lists chromosomal regions, previously
implicated in schizophrenia, that contain genes of the reti-
noid cascade and the retinoic acid receptors. Some of these
are within regions that achieved genome-wide significance in
linkage studies, while others are considered promising (Lerer
et al., 2003; Lewis et al., 2003; Owen et al., 2004). These includ-
ed four of the six retinoic acid receptors, i.e., RARA on chro-
mosome 17q21.2 (for the cytogenetic locations, we used the
updated information available in the UCSC Genome Browser
at http://genome.ucsc.edu), RARB on 3p24.2, RXRB on 6p21.32
and RXRG on 1q23.3 and a variety of the retinoid metabolizing
enzymes and carrier proteins, i.e., cellular retinoic-acid-bind-
ing protein CRABP2 on 1q23.1, lipoprotein lipase on 8p21.3,
RBP1 and RPB2 on 3q23, and ALDH1A1 on 9q21.13. A novel
common locus for narrowly defined schizophrenia and bipo-
lar phenotypes at 15q26.3, the locus of ALDH1A3 has recently
been reported (Maziade et al., 2005). To date, two association
studies have failed to demonstrate significant association of
polymorphisms in the retinoid receptors with schizophrenia
(Feng et al., 2005; Ishiguro et al., 2002). Feng et al. (Feng et al.,
2005) found a non-significant trend towards association iden-
tifying the RARB mutation in 4/498 schizophrenia patients vs.
1/509 non-schizophrenia individuals. However, a modestly
larger replication study failed to significantly confirm the as-
sociation of the mutation with the disease. In cases in which
the SNP is rare, much larger sample sizes would be needed to
achieve sufficient statistical power as has been shown in the
work identifying the rare BRCA1 mutation in breast cancer
(Friedman et al., 1994).
TAAR1, liganded by the thyroid hormone derivative 3-
iodothyronamine, is located within the TAAR cluster at chro-
mosome 6q23.2, a region linked to schizophrenia by several
genome studies (Levi et al., 2005; Owen et al., 2004; Venken
et al., 2005). Several different SNPs in TRAR4/TAAR6 have
recently been identified in both schizophrenia (Duan et al.,
2004) and bipolar disorder (Abou Jamra et al., 2005). Other
genome-wide scan studies, still to be replicated, implicate
chromosomal regions harboring several genes involved in
thyroid hormone metabolism, namely deiodinase type I onchromosome 1p32.3 (Fallin et al., 2003), THRB on 3p24.2 (Pul-
ver et al., 1995) and UDP glucuronosyltransferases on 2q37.1
(Lerer et al., 2003; Wijsman et al., 2003). Therefore, the loci of
many genes of the retinoid and thyroid hormone metabolic
cascades and genes whose expression they regulate have
been often implicated in schizophrenia. Relevant support
for this involvement comes from studies in rodents in
which the expression of nuclear receptors and genes in-
volved in thyroid hormone and retinoid metabolism is influ-
enced by subchronic and acute treatment with drugs such as
haloperidol and clozapine (Eravci et al., 2000; Langlois et al.,
2001; Werme et al., 2000).4. Schizophrenia candidate genes regulated by
retinoic acid and thyroid hormones
The genetic cascades that make ligands available to activate
nuclear transcription factors at specific times in development
and at specific brain locations are complex. Normal allelic
variants in any of the metabolic enzymes of the cascade or
of the ligand transporters could combine to alter ligand avail-
ability. Or nutrient fluctuations due to dietary or infectious
insults could synergize with this variety of alleles to finally tip
the careful balance between deprivation and toxicity, impact-
ing on the genetic expression of target schizophrenia candi-
date genes. Or gene silencing through methylation or
chromatin remodeling (Sharma, 2005) could impact numerous
candidate genes co-localized near the nuclear transcription
factors that control the expression of these candidates (Good-
man and Pardee, 2000).
Retinoid and thyroid hormone involvement in susceptibil-
ity to schizophrenia might result either from mutations or
polymorphisms in genes of their metabolism or whose ex-
pression they regulate but may also result from the altered
expression of these normal genes. Few studies to date have
focused on the search for polymorphisms in these genes. An
association with thyroid disease and schizophrenia has been
reported with a polymorphism on the HOPA gene that codes
for a nuclear receptor coactivator (DeLisi et al., 2000; Spinks et
al., 2004). NR4A2, the human homolog of mouse Nurr1, is
another interesting gene that codes for an orphan nuclear
receptor. It heterodimerizes with RXR, and its function is es-
sential for the development of the dopaminergic system (Zet-
terström et al., 1997). Mutations on the NR4A2 gene have been
described in Swedish, but not American Caucasian patients
with schizophrenia (Buervenich et al., 2000), and in patients of
European descent with Parkinson's disease (Le et al., 2003).
We were unable to find any of these mutations in Portuguese
or Brazilian patients with schizophrenia (Ruano et al., 2004).
Ongoing studies in our laboratory focus on the search for
polymorphisms in other candidate genes of these cascades.
4.1. Retinoids and estrogens
The complexity and diversity of pathways in which retinoids
and thyroid hormones are involved result from their ability
to interact with several other hormonal and neurotransmit-
ter pathways previously implicated in schizophrenia. Among
these are estrogens, which have been thought to be
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males develop schizophrenia of greater severity and at a
significantly earlier age than females, although the estro-
gen-specific mechanism involved is not well understood. It
has now been shown that estrogen directly induces the ex-
pression of the RA-synthesizing enzymes, retinol dehydroge-
nase and retinaldehyde dehydrogenase 2 and the RA
transporter CRABP2 in epithelial and stromal cells of the
liver (Li et al., 2004). If this proves to be the case in other
cell types, a novel connection could be envisaged for the
brain. This connection suggests coordinated activation and
subsequent signaling by estrogen and retinoic acid in the
epithelial and stromal cells of the brain, i.e., the choroid
plexus, where lipid retinoid is carried across the CSF/brain
barrier and the meninges where retinaldehyde dehydroge-
nase is synthesized (Crandall et al., 2004). Upon crossing the
CSF/brain barrier, RA synthesis occurs in areas bordering the
limbic system of the hippocampus and the dorsolateral pre-
frontal cortex (Smith et al., 2001; Yamamoto et al., 1998),
parts of the brain primarily involved in schizophrenia (Anto-
nova et al., 2004). Increased retinoid signaling in estrogen-
replete females could account in part for the protective role
of retinoids and estrogen in this group of schizophrenia
patients.
4.2. Altered gene expression in schizophrenia
Microarray analysis of post-mortem brain tissue from
patients with schizophrenia has revealed alterations in the
expression pattern of genes belonging to several neurotrans-
mitter, signal transduction and metabolic pathways. Howev-
er, care should be taken in interpreting the data obtained in
these studies. For the most part, it is still unclear whether
altered expression occurs before or after disease onset and
whether it is a consequence of medication. It is also possible
that the most relevant alterations in gene expression occur
before disease onset and no longer are reflected in diseased
brain. In any case, these studies are important in proposing
mechanisms of disease for further investigation. Of relevance
to our discussion, myelination, neurotransmission, signal
transduction, synaptic function and mitochondrial activation,
processes that are impaired in the schizophrenic brain, are
directly or indirectly regulated by thyroid hormones and/or
vitamin A. Several candidate genes recently singled out as
significantly contributing to increased vulnerability in schizo-
phrenia (Hakak et al., 2001; Hall et al., 2004; Harrison and
Weinberger, 2005; Kuromitsu et al., 2001; Shirts and Nimgaon-
kar, 2004) are directly or indirectly regulated by thyroid hor-
mone and retinoic acid. Among these are ERBB4, the receptor
for neuregulin 1 (Offterdinger et al., 1999); neuropeptide Y
(Magni, 2003); NOTCH4 (Ye et al., 2004); DRD2 (Samad et al.,
1997); PHOX2B, a transcription factor for RGS4 (Grillet et al.,
2003; Shoba et al., 2002); dysbindin (through retinoid regula-
tion of the expression of dystrophin-associated protein com-
plex (Ceccarini et al., 2002)); prohormone convertases 1 and 3
(Shen et al., 2004); and amyloid-beta protein (Villa et al., 2004)
and myelin-related genes (see below).
Myelination is a paradigmatic example of the temporal
involvement of thyroid hormones and retinoids in regulating
an essential neuronal process that has been implicated inschizophrenia. Myelination is a neurodevelopmental pathway
regulated by thyroid hormones (Rodriguez-Pena, 1999). It has
been argued that a defect in myelination of key corticolimbic
pathways could be related to development of schizophrenia
(Keshavan and Hogarty, 1999), and altered expression of my-
elin-related genes has been found in post-mortem schizo-
phrenic brains (Hakak et al., 2001). Myelination is a process
that continues into early adulthood and into midlife. Interest-
ingly, the observation that males have an earlier onset of
schizophrenia might be a consequence of their delay in mye-
lination during adolescence (Keshavan and Hogarty, 1999).
Hypothyroidism is associated with delayed myelination in
several brain regions (Farsetti et al., 1992; Ibarrola and Rodri-
guez-Pena, 1997). Myelination may later be normalized
through subsequent upregulation of expression of myelin
basic protein, the transcription of which is activated by 9-cis
RA (Pombo et al., 1999). This is an example of the temporal
involvement of several environmental factors in the regula-
tion of essential neuronal processes and in which thyroid
hormone and retinoic acid pathways interplay. In a microar-
ray study of chronic schizophrenia, most of the myelination-
related genes shown to be differentially downregulated, in-
cluding cyclic nucleotide phosphodiesterase, myelin-associat-
ed glycoprotein, transferrin and ERBB3 (Hakak et al., 2001;
Yang et al., 2005) are, themselves, regulated by retinoic acid
and thyroid hormone.
New findings add direct and independent molecular sup-
port to the hypothesis that retinoids and thyroid hormones
may increase vulnerability to schizophrenia: (1) the recent
discovery of the specific differential upregulation of RARA in
granule cells of the dentate gyrus in schizophrenia (Rioux and
Arnold, 2005); (2) the report that RBP4 is highly expressed in
association and limbic cortex of adult primate brains
(Komatsu et al., 2005), regions specifically implicated in
schizophrenia (Heinz et al., 2003); (3) a recent microarray
study showing the retinoic acid receptor as a top functional
gene group altered in schizophrenia (Middleton et al., 2005);
(4) the observation that albumin and ALDH1A1, proteins in-
volved in the transport and synthesis of thyroid hormone and
RA, respectively, are highly significantly differentially
expressed in a microarray study of schizophrenia brains
(Goodman, 2005; Prabakaran et al., 2004); (5) the independent
immunohistochemical confirmation that ALDH1A1 is de-
creased in the ventral tegmental area in schizophrenia (Galter
et al., 2003); (6) evidence showing that the drug, Accutane,
which is a retinoic acid analogue, causes altered brain func-
tion and decreased metabolism in the orbitofrontal cortex of
Accutane-treated acne patients compared to acne patients
not so treated (Bremner et al., 2005); and (7) the demonstration
that Accutane causes decrease in hippocampal size and learn-
ing ability in exposed mice (Crandall et al., 2004).5. Conclusions
The available information on candidate genes involved in
schizophrenia, both at the level of genetic mutations or as a
consequence of altered expression of normal genes, suggests
hormones and vitamins as potential bridges between the ge-
netic and environmental components of the disease. It is
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ARTICLE IN PRESSpresently clear that several pathways and cross-talk between
retinoids, thyroid hormones and other members of the nucle-
ar receptor superfamily interact intimately and completely
with environmental factors influencing the incorporation of
hormones and vitamins into the organism, thusmaking these
systems equally sensitive to both “nurtural” and “natural”
factors. As others, we believe that investigating entire biolog-
ical pathways rather than single genes will greatly contribute
to more precise understanding of their potential involvement
in schizophrenia. Much further laboratory work must be com-
pleted before it will be possible to synthesize the implications
of the hard data now beginning to emerge which strongly
suggest that dysregulation of the retinoid and/or thyroid hor-
mone cascades may represent common underlying pathways
which defectively cross-talk in the development of
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